Long time no post because BTA and others destroyed my faith in investing in biotech.
Anyway, just another example of no faith was the DS bonus due to reaching an Inavir sales milestone. Of course Aviragen management did not factor on this milestone being reached (or did they quietly expect it?) despite trends of a bad flu season, so would not have considered long suffering holders and a potential share bonus in negotiations as part of the Vaxart deal. I'm wondering however whether there was consideration of potential milestones in private negotiations around management packages? We'll never know.
BTA Price at posting:
57.0¢ Sentiment: None Disclosure: Held
